A phase I, open-label study of trebananib combined with sorafenib or sunitinib in patients with advanced renal cell carcinoma (Q28304566)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24365125%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

title

A phase I, open-label study of trebananib combined with sorafenib or sunitinib in patients with advanced renal cell carcinoma (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24365125%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

1 reference

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24365125%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24365125%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Razelle Kurzrock

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24365125%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

David S Hong

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24365125%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Michael S Gordon

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24365125%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Nizar Tannir

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24365125%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

David Friedland

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24365125%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

David S Mendelson

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24365125%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Nicholas J Vogelzang

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24365125%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Erik Rasmussen

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24365125%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Benjamin M Wu

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24365125%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Michael B Bass

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24365125%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Zhandong D Zhong

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24365125%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Gregory Friberg

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24365125%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

language of work or name

English

0 references

publication date

13 November 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24365125%20AND%20SRC:MED&resulttype=core&format=json

Clinical Genitourinary Cancer

3 March 2020

published in

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24365125%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

volume

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24365125%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

issue

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24365125%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

page(s)

167-177.e2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24365125%20AND%20SRC:MED&resulttype=core&format=json

Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma

3 March 2020

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4754667

Sorafenib in advanced clear-cell renal-cell carcinoma

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4754667

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4754667

Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4754667

Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4754667

Angiogenesis: an organizing principle for drug discovery?

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4754667

Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4754667

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4754667

AMG 386 in combination with sorafenib in patients with metastatic clear cell carcinoma of the kidney: a randomized, double-blind, placebo-controlled, phase 2 study.

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4754667

Exposure-response relationship of AMG 386 in combination with weekly paclitaxel in recurrent ovarian cancer and its implication for dose selection

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4754667

Context-Dependent Role of Angiopoietin-1 Inhibition in the Suppression of Angiogenesis and Tumor Growth: Implications for AMG 386, an Angiopoietin-1/2–Neutralizing Peptibody

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4754667

Biomarkers as predictors of response to treatment with motesanib in patients with progressive advanced thyroid cancer.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4754667

Resistance to targeted therapy in renal-cell carcinoma

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4754667

Circulating levels of soluble KIT serve as a biomarker for clinical outcome in gastrointestinal stromal tumor patients receiving sunitinib following imatinib failure

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4754667

Tumor and host-mediated pathways of resistance and disease progression in response to antiangiogenic therapy.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4754667

Combination targeted therapy in advanced renal cell carcinoma

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4754667

Phase I trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinoma.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4754667

Angiopoietin-1/Tie-2 activation contributes to vascular survival and tumor growth during VEGF blockade

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4754667

Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4754667

Sunitinib: from rational design to clinical efficacy

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4754667

Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4754667

Angiopoietin-2 expression in breast cancer correlates with lymph node invasion and short survival.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4754667

Soluble Kit receptor blocks stem cell factor bioactivity in vitro

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4754667

Expression of angiogenesis stimulators and inhibitors in human thyroid tumors and correlation with clinical pathological features

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4754667

Trebananib (AMG 386) in Combination With Sunitinib in Patients With Metastatic Renal Cell Cancer: An Open-Label, Multicenter, Phase II Study.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4754667

Safety, pharmacokinetics, and antitumor activity of AMG 386, a selective angiopoietin inhibitor, in adult patients with advanced solid tumors

27 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4754667

Salvage therapy with bevacizumab-sunitinib combination after failure of sunitinib alone for metastatic renal cell carcinoma: a case series

27 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4754667

Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma.

27 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4754667

Serum KIT and KIT ligand levels in patients with gastrointestinal stromal tumors treated with imatinib

27 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4754667

Placental growth factor is a survival factor for tumor endothelial cells and macrophages

27 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4754667

Angiopoietin-2 is related to tumor angiogenesis in gastric carcinoma: possible in vivo regulation via induction of proteases

27 November 2018

1 reference

12 December 2020

Randomized, double-blind, placebo-controlled phase II study of AMG 386 combined with weekly paclitaxel in patients with recurrent ovarian cancer

1 reference

12 December 2020

Sunitinib-induced changes in circulating endothelial cell-related proteins in patients with metastatic renal cell cancer

1 reference

12 December 2020

c-KIT: potential predictive factor for the efficacy of sorafenib in metastatic renal cell carcinoma with sarcomatoid feature

1 reference

12 December 2020

Identification and inhibition of drug target interference in immunogenicity assays

1 reference

12 December 2020

10.1016/J.CLGC.2013.11.007

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24365125%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24365125%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

PubMed publication ID

24365125

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24365125%20AND%20SRC:MED&resulttype=core&format=json